Eli Lilly hasn’t been shy about making deals to build up its cancer immunotherapy pipeline, and its latest one is with NextCure, a biotech with technology that finds molecular targets to drive an immune response to tumors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,